ERBB2 and colorectal carcinoma: From a predictive point of view, apart from its well-known use as a predictive tissue biomarker for anti-HER2 treatment, and its amplification or overexpression, as well as HER2-activating mutations, have been associated with a lack of response to anti-EGFR drugs, as seen in a cohort of 233 patients with CRC receiving cetuximab [85].